Listed by the USPTO as HADDAD, MAHER M
Tech Center 1600 • Art Units: 1622 1634 1641 1644
This examiner grants 51% of resolved cases
HADDAD, MAHER M is a USPTO patent examiner in tech center 1600 and art unit 1622. The profile includes 1072 resolved cases, a 50.6% allowance rate, and a median of 1121 days to allowance. The 53.8% interview lift is the most prominent prosecution signal in the profile, associating interviews with a materially higher allowance outcome in the measured data.
Takeda Pharmaceutical Company Limited, Millennium Pharmaceuticals Inc., and Novartis AG are the leading companies. The most frequently appearing firms are FISH & RICHARDSON P.C. (TC), Kilpatrick Townsend & Stockton LLP - West Coast, and BALLARD SPAHR LLP. Counsel can use these patterns when evaluating examiner-specific experience in pharmaceutical and related technology matters.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17616900 | Use of an Anti-P-selectin Antibody | Final Rejection | NOVARTIS AG |
| 18271205 | MODULATION OF CD46 CELL SURFACE EXPRESSION AND THERAPEUTIC USE THEREOF | Final Rejection | The Regents of the University of California |
| 18279191 | HIGH POTENCY T CELL RECEPTORS FOR IMMUNOTHERAPY | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18035054 | METHODS FOR ADMINISTERING A BCMAXCD3 BINDING MOLECULE | Final Rejection | AMGEN INC. |
| 17609757 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Non-Final OA | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS |
| 18551679 | METHODS OF TREATING CANCER IN IMMUNOSUPPRESSED OR IMMUNOCOMPROMISED PATIENTS BY ADMINISTERING A PD-1 INHIBITOR | Non-Final OA | Sanofi Biotechnology |
| 18256565 | COMPOSITIONS OF GUANYLYL CYCLASE C (GCC) ANTIGEN BINDING AGENTS AND METHODS OF USE THEREOF | Final Rejection | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 16208294 | FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY AND METHODS OF TREATMENT | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 18700535 | MOLECULES THAT BIND TO CD276 POLYPEPTIDES | Non-Final OA | University of Pittsburgh of the Commonwealth System of Higher Education |
| 18254606 | NOVEL CONJUGATE MOLECULES TARGETING CD39 AND TGFBETA | Final Rejection | ELPISCIENCE BIOPHARMA, LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy50.6% of resolved applications examined by Maher M Haddad were allowed (1,072 resolved cases), compared with 60.6% across Art Unit 1622 over the last five years.
This examiner's interview lift is +53.8 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Maher M Haddad took 1,121 days on average from filing to allowance.
Maher M Haddad examines applications in Art Unit 1622 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
